Antifungal combination therapy for invasive aspergillosis.
Clin Infect Dis. 2014 Jul 21;
Authors: Martín-Peña A, Aguilar-Guisado M, Espigado I, Cisneros JM
Abstract
The outcome of invasive aspergillosis (IA) continues to be associated with significant attributable mortality, especially in patients with hematological malignancies and hematopoietic stem cell transplant (HSCT) recipients. In this context, antifungal combined therapy (ACT) has become an emerging strategy against IA. In an attempt to evaluate the benefits of ACT, a large number of experimental studies, clinical series and randomized trials have been reported, with varying results. In addition, several controlled trials have been registered, however in most cases their final results have not been made available. In summary, there is an imbalance between the weak level of published evidence regarding the benefits of ACT and its high and rising use in current clinical practice, despite its associated cost. In this viewpoint a critical analysis of the available information regarding ACT for the treatment of IA is discussed and the opinion of the authors with respect to its use is presented.
PMID: 25048847 [PubMed - as supplied by publisher]